Home Cart Sign in  
Chemical Structure| 72496-41-4 Chemical Structure| 72496-41-4

Structure of Pirarubicin
CAS No.: 72496-41-4

Chemical Structure| 72496-41-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pirarubicin is an analogue of the anthracycline anti-neoplastic doxorubicin, which is an inhibitor of Topo II.

Synonyms: THP; NSC-333054

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pirarubicin

CAS No. :72496-41-4
Formula : C32H37NO12
M.W : 627.64
SMILES Code : O=C1C2=C(C=CC=C2OC)C(C3=C(O)C4=C([C@@H](O[C@@]5([H])C[C@H](N)[C@H](O[C@@]6([H])OCCCC6)[C@H](C)O5)C[C@@](C(CO)=O)(O)C4)C(O)=C31)=O
Synonyms :
THP; NSC-333054
MDL No. :MFCD00869742

Safety of Pirarubicin

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H340-H350-H360
Precautionary Statements:P201-P202-P280-P308+P313-P8624-P405-P501

Related Pathways of Pirarubicin

DNA

Isoform Comparison

Biological Activity

Target
  • Topo II

In Vitro:

Cell Line
Concentration Treated Time Description References
H9C2 cardiomyocytes 5 μM 22 h Establish THP-induced cell injury model, THP significantly decreased cell activity PMC8554014
MDA-MB-468 3 μM 24 h To study the effect of THP on circZCCHC2 expression in MDA-MB-468 cells, the results showed that THP significantly downregulated circZCCHC2 expression. PMC10867422
MDA-MB-231 5 μM 24 h To study the effect of THP on circZCCHC2 expression in MDA-MB-231 cells, the results showed that THP significantly downregulated circZCCHC2 expression. PMC10867422
MDA-MB-231 cells 20 μg/mL 2 h To evaluate the cellular uptake and drug release of P60-ICG-THP triggered by acidic pH, the results showed that THP could immediately cross the cell membrane and enter the nucleus at pH 6.5, while ICG was mainly located in the cytoplasm. PMC7667678
HCM cells 5 μM 24 h To evaluate the effect of Pirarubicin on the survival rate of HCM cells, the results showed that 5 μM Pirarubicin treatment for 24 h significantly reduced cell viability. PMC10982373
H9c2 cells 5 μM 24 h To evaluate the effect of Pirarubicin on the survival rate of H9c2 cells, the results showed that 5 μM Pirarubicin treatment for 24 h significantly reduced cell viability. PMC10982373

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Xenograft tumor model Tail vein injection 5 mg/kg Once a week for four weeks To study the effect of circZCCHC2 on THP sensitivity in vivo, the results showed that circZCCHC2 overexpression partially rescued the tumor inhibitory effect of THP. PMC10867422
Nude mice MDA-MB-231 tumor model Caudal vein injection 20 mg/kg Once daily for 21 days To evaluate the antitumor effect of P60-ICG-THP in vivo, the results showed that P60-ICG-THP significantly inhibited tumor growth through the combination of chemotherapy, photothermal therapy, and starvation therapy. PMC7667678
Wistar rats Pirarubicin-induced cardiotoxicity model Caudal vein injection 3 mg/kg Once a week for 6 weeks To evaluate the effect of Pirarubicin on cardiotoxicity in rats, the results showed that Pirarubicin significantly reduced cardiac function and increased serum levels of myocardial enzymes. PMC10982373
SD rats THP-induced cardiotoxicity model Caudal vein injection 3 mg/kg Once a week for 8 weeks To study THP-induced cardiotoxicity and observe the protective effect of SchB. THP caused decreased and food intake, abnormal ECG and echocardiogram, myocardial tissue damage, and increased cardiomyocyte apoptosis, which were effectively alleviated by SchB PMC8554014

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03277716 Hepatocellular Carcinoma Non-r... More >>esectable Transarterial Chemoembolization Microwave Ablation Less << Not Applicable Recruiting December 30, 2021 China, Beijing ... More >> Cancer Institute &Hospital, Chinese Academy of Medical Sciences Not yet recruiting Beijing, Beijing, China, 100021 Contact: Xiao Li, M.D          China, Fujian The First Affiliated Hospital of Fujian Medical University Recruiting Fuzhou, Fujian, China, 350005 Contact: Zhenyu Lin, M.D.          The tumor hospital of Fujian Province Not yet recruiting Fuzhou, Fujian, China, 350014 Contact: Hailan Lin, M.D          China, Guangdong the First Affiliated Hospital of SunYat-senUniversity Not yet recruiting Guangzhou, Guangdong, China, 510080 Contact: Jiaping Li, M.D          Shenzhen People's Hospital Recruiting Shenzhen, Guangdong, China, 518020 Contact: Yanfang Zhang, M.D.          Peking University Hospital of Shenzhen Recruiting Shenzhen, Guangdong, China, 518036 Contact: Junhui Chen, M.D.          China, Shandong The Second Affiliated Hospital of Shandong University Recruiting Jinan, Shandong, China, 250000 Contact: Yuliang Li, M.D          Shandong Province Hospital Recruiting Jinan, Shandong, China, 250014 Contact: Xin Ye, M.D          the Affiliated Hospital of Medical College Qingdao University Recruiting Qingdao, Shandong, China, 26555 Contact: Zixiang Li, M.D          China, Zhejiang The First Affiliated Hospital of Zhejiang University Not yet recruiting Hangzhou, Zhejiang, China, 310003 Contact: Junhui Sun, M.D. Less <<
NCT00131053 Lymphoblastic Leukemia, Acute Phase 2 Unknown September 2011 Japan ... More >> Department of Hematology, Nagoya University Graduate School of Medicine Recruiting Nagoya, Japan, 466-8550 Contact: Fumihiko Hayakawa, MD       bun-hy@med.nagoya-u.ac.jp    Principal Investigator: Fumihiko Hayakawa, MD Less <<
NCT02760953 Urinary Bladder Neoplasms Not Applicable Not yet recruiting December 31, 2018 -
NCT02435953 Hepatocellular Carcinoma ... More >> Chemoembolization, Therapeutic Ablation Techniques, RFA Less << Phase 4 Recruiting - China, Guangdong ... More >> Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center, Recruiting Guangzhou, Guangdong, China, 500060 Contact: Ming Zhao, doctor    +86 020 87343272    zhaoming@sysucc.org.cn    Contact: Tao Pan, doctor    +86 020 87343271    pantao0909@hotmail.com Less <<
NCT03503864 Neuroblastoma Phase 2 Recruiting December 30, 2029 China, Guangdong ... More >> Sun Yat-sen Memorial Hospital, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510120 Contact: Yang Li, Professor    +8602081332456    drliyang@126.com Less <<
NCT01430013 T Cell Lymphoma Phase 2 Unknown December 2015 China, Tianjin ... More >> Tianjin Medical University Cancer Institute and Hospital Tianjin, Tianjin, China, 300060 Less <<
NCT02956772 Primary Hepatocellular Carcino... More >>ma Less << Phase 2 Not yet recruiting November 2020 China, Guizhou ... More >> Guizhou Cancer Hospital Not yet recruiting Guiyang, Guizhou, China Contact: Shi Zhou, Dr.       258600801@qq.com    Guizhou Province Tumor Hospital Not yet recruiting Guiyang, Guizhou, China Contact: Junxiang Li, Dr.       258600801@qq.com    China, Hunan Hunan Provincial People's Hospital Not yet recruiting Changsha, Hunan, China, 410001 Contact: Hua Xiang, Dr.    +86-13667367061       Contact: Lin Long, Dr.    +86-13507476175    doclongll@163.com    Hunan Cancer Hospital Not yet recruiting Changsha, Hunan, China Contact: Guowen LI, Dr.       liguowen@hnszlyy.com    Xiangya Hospital Central South University Not yet recruiting Changsha, Hunan, China Contact: Chunhui Zhou, Dr.       zhouchunhui2016@163.com    The First Affiliated Hospital of University of South China Not yet recruiting Hengyang, Hunan, China Contact: Youhua Wu, Dr.       330270372@qq.com    China, Jiangsu Jiangsu Province Hospital Not yet recruiting Nanjing, Jiangsu, China Contact: Zhen-Qiang Yang, Dr.       ntdoctoryang@hotmail.com    China, Xinjiang Xinjiang Medical University Cancer Hospital Not yet recruiting Urumqi, Xinjiang, China Contact: Shufa Yang, Dr.       yangshufa2013@sina.com    China, Yunnan The Tumor Hospital of Yunnan Province Not yet recruiting Kunming, Yunnan, China Contact: Ming Huang, Dr.       huangming4328@sina.com Less <<
NCT02396043 Lymphoma, Lymphoblastic Phase 2 Recruiting March 2020 China, Guangdong ... More >> Sun Yat-sen University Cancer Center Recruiting GuangZhou, Guangdong, China, 510060 Contact: Zhongjun Xia, MD.    0086-02087342438    zhongjunxia_64@sina.com Less <<
NCT03121833 Soft Tissue Sarcoma, Adult, St... More >>age IIB Less << Phase 2 Recruiting May 1, 2019 China, Tianjin ... More >> Tianjin Medical University Cancer Hospital & Institute Recruiting Tianjin, Tianjin, China, 300060 Contact: Jilong Yang, M.D., Ph.D.    +8618622221626    yangjilong@tjmuch.com Less <<
NCT02301091 Hepatocellular Carcinoma Phase 3 Recruiting October 2019 China, Guangdong ... More >> Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center, Recruiting Guangzhou, Guangdong, China, 500060 Contact: Ming Zhao, doctor    +86 020 87343272    zhaoming@sysucc.org.cn Less <<
NCT02838225 Breast Cancer Phase 2 Completed - -
NCT02525952 Hepatocellular Carcinoma Not Applicable Unknown December 2017 China, Shanghai ... More >> Eastern hepatobilliary surgery hospital Recruiting Shanghai, Shanghai, China, 200438 Contact: Yong Xia, Doctor    86-021-81875495       Eastern hepatobilliary surgery hospital Recruiting Shanghai, Shanghai, China, 200438 Contact: Shen Feng, MD    0086-021-25070805    shenfengdfgd@yahoo.com.cn    Contact: Wu Dong, MD    0086-021-25070765    wuyuz@yahoo.com.cn    Principal Investigator: Shen Feng, MD Less <<
NCT02724358 Hepatocellular Carcinoma ... More >> TACE Notch1 Rg3 Less << Not Applicable Completed - China, Shanghai ... More >> Eastern hepatobilliary surgery hospital Shanghai, Shanghai, China, 200438 Less <<
NCT02953184 Antineoplastic Combined Chemot... More >>herapy Protocols Less << Phase 2 Recruiting November 2020 China, Jilin ... More >> First Hospital of Jilin University Recruiting Changchun, Jilin, China, 130021 Contact: Aiping Shi, Doctor    0086-13364308696    13364308696@163.com    Contact: Zhimin Fan, Doctor    0086-13756661286    fanzhimn@163.com    Sub-Investigator: Di Wu, Doctor          Sub-Investigator: Hongyao Jia, Master          Sub-Investigator: Xin Guan, Master          Principal Investigator: Zhimin Fan, Doctor          Principal Investigator: Haibo Wang, Doctor          Sub-Investigator: Gang Nie, Doctor Less <<
NCT02585479 Hepatocellular Carcinoma Phase 2 Phase 3 Unknown October 2017 -
NCT02584556 Hepatocellular Carcinoma Phase 2 Phase 3 Unknown October 2017 -
NCT02755311 Hepatocellular Carcinoma Phase 3 Unknown June 2016 China, Guangdong ... More >> The First Affiliated Hospital of Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510080 Contact: Zhenwei Peng, MD       pengzhenwei2005@163.com Less <<
NCT02547350 Upper Tract Urothelial Carcino... More >>ma Bladder Recurrence Less << Phase 2 Not yet recruiting - -
NCT02740426 Upper Tract Urothelial Carcino... More >>ma|Bladder Recurrence Less << PHASE2 UNKNOWN 2025-05-22 Peking University First Hospit... More >>al, Beijing, Beijing, 100034, China Less <<
NCT02613026 Breast Neoplasms Phase 3 Completed - China, Hebei ... More >> The fourth hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050010 China, Heilongjiang Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China, 150081 China, Hunan Hunan Provincial People's Hospital Changsha, Hunan, China, 410005 Xiangya Hospital, Central South University Changsha, Hunan, China, 410008 China, Jiangsu Jiangsu Cancer Hospital Nanjing, Jiangsu, China, 210000 Less <<
NCT02923557 Bladder Recurrence|Upper Tract... More >> Urothelial Carcinoma|Nephroureterectomy Less << PHASE2 UNKNOWN - Peking University Frist Hospit... More >>al, Beijing, Beijing, 10034, China Less <<
NCT01249690 Multiple Myeloma Phase 4 Unknown June 2014 China, Shang Hai ... More >> Shanghai Changzheng Hospital Recruiting Shang Hai, Shang Hai, China, 200003 Contact: Hou       houjian_czyy@sina.cn    Principal Investigator: Jian Hou Less <<
NCT01746992 ALK-negative Anaplastic Large ... More >>Cell Lymphoma Peripherial T Cell Lymphoma,Not Otherwise Specified Angioimmunoblastic T Cell Lymphoma Enteropathy Associated T Cell Lymphoma Hepatosplenic T Cell Lymphoma Subcutaneous Panniculitis Like T Cell Lymphoma Less << Phase 4 Active, not recruiting December 2018 China, Shanghai ... More >> Ruijin hospital Shanghai, Shanghai, China, 200025 Less <<
NCT02903524 Breast Cancer Phase 4 Unknown December 2018 China, Hebei ... More >> Fourth Hospital of Hebei Medical University Recruiting Shi Jiazhuang, Hebei, China, 050019 Contact: Geng Cuizhi, archiater    0311-66696310    gengcuizhi@hotmail.com Less <<
NCT03030157 Intravesical Instillation Phase 2 Recruiting - China, Shanghai ... More >> Renji Hospital Recruiting Shanghai, Shanghai, China, 200127 Contact: jiwei huang, M.D    8613651682825    jiweihuang@outlook.com    Contact: jin zhang    86-21-68383776    zhangjin@renji.com Less <<
NCT03342300 Progression-free Survival ... More >> Overall Survival Toxicity Less << Phase 2 Phase 3 Recruiting December 30, 2019 China ... More >> Peking University People's Hospital Recruiting Beijing, China, 100044 Contact: Tingting Ren, Ph.D.    +86-13810095026    tumorcenter@163.com    Principal Investigator: Wei Guo, M.D. and Ph.D. Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.59mL

0.32mL

0.16mL

7.97mL

1.59mL

0.80mL

15.93mL

3.19mL

1.59mL

References

 

Historical Records

Categories